Navigation Links
Noninvasive test for trisomy 21 closer at hand
Date:2/10/2011

St. Louis, MO, February 10, 2011 In 1980 in the United States, approximately 4.5% of all pregnant women were of advanced maternal age. By 2007 that figure had increased to 14%. Women over 35 are at increased risk of giving birth to babies with trisomy 21. In a study published online today in the American Journal of Obstetrics & Gynecology (AJOG), researchers from the Sequenom Center for Molecular Medicine confirmed that DNA sequencing of maternal blood plasma could accurately detect trisomy 21.

"In this study we have taken the next step in evaluating the practical use of fetal DNA sequencing and have shown that it has the potential to be highly accurate in a clinical setting," commented senior author Dirk van den Boom, DPhil. "We have implemented technical improvements that will increase sample throughput and reduce costs. Following completion of an ongoing clinical validation study the above improvements will greatly facilitate introduction into clinical practice. "

Because the plasma of pregnant women contains circulating cell-free (ccf) fetal (ccff) DNA the DNA sequencing method is able to identify the extra chromosome 21 material present in a fetus with trisomy 21. Independent of gestational age assessments, this novel approach allows for direct fetal assessment using massively parallel shotgun sequencing to detect missing or extra chromosomes, rather than surrogate biochemical markers that are used today in clinical practice.

Using samples from 449 high-risk pregnant women, the DNA sequencing method correctly identified 39 trisomy 21 samples and 409 normal samples, and misclassified 1 normal sample as trisomy 21. The overall classification showed 100% sensitivity and 99.7% specificity.

The data show that, in the future, a noninvasive prenatal trisomy 21 test from ccff DNA might be used in concert with other clinical assessments, such as ultrasound, and become an option to better identify those women who would, or would not, benefit from confirmatory invasive diagnostic tests.

According to prenatal testing expert, Lee P. Shulman MD, The Feinberg School of Medicine of Northwestern University, Chicago, "The results of this study point more to a continuation in the improvement in the various non-invasive aneuploidy detection technologies that have been studied for the past two decades; hence, the results of this study can be considered a small step...Many more steps and studies will be needed in order to arrive at the goal that most of us who provide and study prenatal screening and diagnosis have long sought after: a facile, economical, and more accurate approach to prenatal screening and, eventually, an effective noninvasive alternative to invasive prenatal testing. We may not be there yet, but it seems that we have come a bit closer to our ultimate objective."

"This important study, along with another article recently published, suggests that progress is being made towards the realization of prenatal diagnosis of fetal disorders based upon maternal blood analysis and the use of high throughput technologies. While this study shows feasibility for the detection of trisomy 21, further studies are required to establish utility in clinical practice. A new frontier is the diagnosis, not only of trisomy 21 and other genetic disorders of the human fetus, but also the assessment of the functional state of the unborn baby by analysis of circulating fetal and/or placental RNA in the maternal circulation," said Roberto Romero, Chief of the Perinatology Research Branch of NICHD, NIH and Professor of Molecular Obstetrics and Genetics at Wayne State University. Dr. Romero is an Associate Editor of the American Journal of Obstetrics & Gynecology.


'/>"/>

Contact: Nancy Burns
ajogmedia@elsevier.com
314-447-8013
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. New research shows innovative respiratory stress test can quickly detect significant coronary artery disease in a noninvasive setting
2. Noninvasive combination technique may reduce number of breast biopsies
3. Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer
4. Noninvasive Test for Colon Cancer Shows Promise in Early Trial
5. Noninvasive brain stimulation helps improve motor function in stroke patients
6. Noninvasive Glaucoma Test Might Speed Up Detection
7. Idaho House Moves State Closer to Health Care Disaster
8. Heart Stem Cells Move Closer to Human Treatments
9. Stevens Hospital One Step Closer to Affiliation with Swedish
10. Mind Reading Moves Closer to Reality
11. Urine test for kidney cancer a step closer to development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: